Pan-Variant SARS-CoV-2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes

Area of Science:

• Immunology
• Vaccine Development
• Virology

Background:

• Developing a globally effective COVID-19 vaccine is challenging due to viral variability.
• Current vaccine strategies struggle to redirect immune responses towards conserved viral domains.

Purpose of the Study:

• To design a novel vaccine strategy targeting conserved B-cell and T-cell epitopes.
• To elicit broad humoral and cellular immunity against diverse SARS-CoV-2 variants.

Main Methods:

• Integrated B-cell epitope prediction, protein-antibody docking, and titer analysis.
• T-cell epitope identification using prediction, differential scanning fluorimetry, and peptide-MHC analysis.
• In vivo and in vitro validation in mice and human cells.

Main Results:

• Identified stable B-cell epitopes eliciting robust antibody responses against SARS-CoV-2 variants.
• Discovered promiscuous T-cell epitopes activating CD4+ and CD8+ T-cells across MHC haplotypes.
• Demonstrated cross-species efficacy and neutralization of pseudoviruses.

Conclusions:

• An integrated approach targeting conserved epitopes is crucial for broad-spectrum COVID-19 vaccines.
• This strategy can overcome challenges posed by viral mutations and variants of concern.
• The identified epitopes offer a promising foundation for next-generation SARS-CoV-2 vaccines.